Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


September 13, 2012 - NHL & CLL Diagnosis and Treatment Update

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: September 13, 2012
Time: 1:00 p.m. - 2:30 p.m. ET
Location: Telephone/Web
View: Program Slides (English) | Program Slides (Spanish) | Program Slides (Portuguese) 
Read: Transcript (English) | Transcript (Spanish)
Listen: Presentation | Q&A Session | Extended Q&A |
Presentation/Q&A Session (Spanish) | Presentation/Q&A Session (Portuguese)
Access: Virtual Lecture

Topics Covered  

  • Signs and symptoms of indolent and aggressive NHL subtypes & CLL
  • Diagnosis and treatment planning for indolent and aggressive NHL subtypes & CLL
  • Current and emerging treatment options for patients with indolent or aggressive NHL subtypes or CLL
  • The importance of clinical trials in improving patient outcomes
  • Side effects management and other survivorship issues for patients
  • The importance of patient-provider communications


Christopher R. Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Questions Asked by the NHL & CLL Community

  • Are there any more clear or definitive criteria for differentiating indolent versus aggressive in chronic lymphocytic leukemia (CLL)?
  • Can people bank their own stem cells while in remission for later use? And if yes, do they last indefinitely or is there a time limit for use?
  • How effective is a mini-transplant for a CLL patient if other treatments are not working?
  • Until what age is a mini-transplant effective?
  • Are there advantages to treating a CLL patient when he/she is diagnosed instead of waiting?
  • Can you explain the phrase 'high tumor burden?'
  • For the diagnosis of diffuse large B cell lymphoma, mediastinal primary, what is the best attempt for biopsy? Is it mediastinoscopy or mediastinotomy?
  • Would you please address what oncologists are recommending in terms of exercise and diet during cancer treatment for non-Hodgkin lymphoma (NHL) and CLL?
  • Please discuss coping with lymphedema in the legs.
  • Can you talk about the difference between virus treatments being done at The University of Pennsylvania and CAL-101 and who benefits from each?
  • Are there any trials being done on the supplement called green tea, the ECGC amount, and what amounts are needed to reduce CLL effects?
  • Is there a correlation between polycythemia vera and CLL or NHL?
  • Does progression of CLL increase as the patient ages?
  • Will a bad tooth infection affect the lymph nodes?
  • Are SYK, BTK and P13IK specific to the treatment of diffuse large B-cell lymphoma?
  • What clinical trials are available for diffuse large B-cell lymphoma and what do the phases mean?
  • Is it true that years after treatment for leukemia or lymphoma, a person is at high risk for developing the other cancer? Why is this?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society in collaboration with Abrale and Alianza Latina and supported by a grant from Genentech and Biogen Idec.

last updated on Thursday, March 19, 2015